Skip Navigation

Adalvo announces successful MA approval for Solifenacin + Tamsulosin

07 October 2022

Adalvo is delighted to announce the successful MA approval of Solifenacin + Tamsulosin in various EU markets.

Our product is a fully bioequivalent version of Vesomni MR Tablets, 6mg/0.4mg. This product has been co-developed in collaboration with one of our strategic partners.

Vesomni is a niche product, indicated in the treatment of moderate to severe storage symptoms (urgency, increased micturition frequency) and voiding symptoms associated with benign prostatic hyperplasia (BPH) in men, who are not adequately responding to treatment with monotherapy.

Based on this positive progress, we will proceed to launch this product, as soon as regulatory exclusivities and patents allow us.

Disclaimer: Products which are subject to patent protection are currently not offered or made available in countries where patents are in force.